[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552011":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":30,"responsibleParty":52,"collaborators":26,"id":54,"slug":26,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":26,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":26,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":26,"overallStatus":32,"whyStopped":26,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","DAOIB plus Antioxidant agent (AO)",[13],"Drug: DAOIB plus AO",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Comparator","PLACEBO_COMPARATOR","DAOIB plus Placebo",[19],"Drug: DAOIB plus placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","DAOIB plus AO","oral, for 24 weeks",[9],null,{"type":22,"name":28,"description":24,"armGroupLabels":29,"otherNames":26},"DAOIB plus placebo",[15],[31],{"facility":5,"status":32,"city":33,"state":26,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Kaohsiung City","886","Taiwan","TW",{"type":38,"coordinates":39},"Point",[40,41],120.31333,22.61626,{"lat":41,"lon":40},[44,50],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Chieh-Hsin Lin, MD, PhD","CONTACT","886-7-7317123","8753","cyndi36@gmail.com",{"name":45,"role":51,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100552011",false,"NCT06467539","Novel Augmentation of DAOIB and Antioxidant for Early Dementia","Inclusion Criteria:\n\n* Clinical diagnosis of Alzheimer's disease or mild cognitive impairment\n* MMSE between 10-26\n* CDR 1 or 0.5\n\nExclusion Criteria:\n\n* Hachinski Ischemic Score \\> 4\n* Substance abuse\u002Fdependence\n* Parkinson disease, epilepsy, dementia with psychotic features\n* Major depressive disorder\n* Major physical illnesses\n* Severe visual or hearing impairment","ALL","50 Years","90 Years",{"count":63,"type":64},80,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.",[70,71],"Alzheimer Disease","Mild Cognitive Impairment","2026-03-18",{"date":74,"type":75},"2026-03-19","ACTUAL",{"date":77,"type":75},"2024-06-19",{"date":79,"type":64},"2027-05",{"name":5,"class":6},1]